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OBJECTIVES: To determine whether kidney disease and hemolysis are associated with bone mass density in a
population of adult Brazilian patients with sickle cell disease.
INTRODUCTION: Bone involvement is a frequent clinical manifestation of sickle cell disease, and it has multiple
causes; however, there are few consistent clinical associations between bone involvement and sickle cell disease.
METHODS: Patients over 20 years of age with sickle cell disease who were regularly followed at the Hematology and
Hemotherapy Center of Campinas, Brazil, were sorted into three groups, including those with normal bone mass
density, those with osteopenia, and those with osteoporosis, according to the World Health Organization criteria.
The clinical data of the patients were compared using statistical analyses.
RESULTS: In total, 65 patients were included in this study: 12 (18.5%) with normal bone mass density, 37 (57%) with
osteopenia and 16 (24.5%) with osteoporosis. Overall, 53 patients (81.5%) had bone mass densities below normal
standards. Osteopenia and osteoporosis patients had increased lactate dehydrogenase levels and reticulocyte
counts compared to patients with normal bone mass density (p,0.05). Osteoporosis patients also had decreased
hemoglobin levels (p,0.05). Hemolysis was significantly increased in patients with osteoporosis compared with
patients with osteopenia, as indicated by increased lactate dehydrogenase levels and reticulocyte counts as well as
decreased hemoglobin levels. Osteoporosis patients were older, with lower glomerular filtration rates than patients
with osteopenia. There was no significant difference between the groups with regard to gender, body mass index,
serum creatinine levels, estimated creatinine clearance, or microalbuminuria.
CONCLUSION: A high prevalence of reduced bone mass density that was associated with hemolysis was found in this
population, as indicated by the high lactate dehydrogenase levels, increased reticulocyte counts and low
hemoglobin levels.
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INTRODUCTION
Sickle Cell Disease (SCD) is an inherited disorder caused
by a point mutation in codon 6 of the b-globin gene. This
mutant form of hemoglobin (HbS) is capable of polymeriza-
tion and complex molecular and structural changes within
the erythrocyte. Hemolytic anemia and vaso-occlusion
crises are the main features of sickle cell disease, and they
occur in homozygotes (HbSS) or in compound heterozy-
gotes, such as those carrying HbS and b-thalassemia (HbSb
+
or HbSb
0) or HbS and hemoglobin C (HbSC). The illness
tends to develop gradually toward multisystem organ
failure.
1
Bone involvement is a frequent clinical manifestation of
sickle cell disease that occurs during the acute phase and
during painful vaso-occlusive crises. Bone involvement is a
source of chronic, progressive disability, such as the long-
term effects of sickle cell disease upon bone mass density
(BMD), growth, and chronic bone damage in the form of
avascular necrosis and osteomyelitis. Osteopenia and
osteoporosis are often asymptomatic; however, pain, frac-
tures, deformities, and vertebral collapse may occur and
require chronic analgesia, mechanical support, and surgical
interventions.
2-6 Several studies have shown an overall
reduction of BMD in children with SCD.
7-9 The causes of
BMD abnormalities in patients with SCD are probably
Copyright  2011 CLINICS – This is an Open Access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.
CLINICS 2011;66(5):801-805 DOI:10.1590/S1807-59322011000500015
801multifactorial. Several factors, including reduced hemoglo-
bin levels, abnormally low body mass index (BMI),
increased ferritin levels, vitamin D deficiencies and low
plasma zinc or sex steroid levels, have been previously
correlated with reduced BMD in adult patients with
SCD.
3,10-13 There are a limited number of studies and
conclusions regarding the risk factors for osteoporosis in
adult SCD patients. The present study aimed to establish the
prevalence of reduced BMD in adult patients with SCD and
examine whether any correlation exists between reduced
BMD and clinical characteristics.
SUBJECTS AND METHODS
The inclusion criteria for this study consisted of patients
over 20 years of age with a precise clinical and laboratory
diagnosis of SCD and regular follow-ups at the Hematology
and Hemotherapy Center of the University of Campinas
(Hemocentro-Unicamp).
All SCD patients who attended this center from March
2007 to June 2008 had their charts reviewed. To be included,
a patient’s chart had to contain all of the following data:
hemoglobin (Hb) electrophoresis, gender, age, BMI (BMI =
weight (kg)/height
2(m
2)), serum creatinine, estimated crea-
tinine clearance, glomerular filtration rate (GFR), micro-
albuminuria, hemoglobin (Hb) levels, reticulocyte counts,
serum lactate dehydrogenase (LDH) levels, and a BMD
assessment. Microalbuminuria was measured using the
nephelometric method with nocturnal 12-hour urine.
15
Creatinine clearance was estimated by the Cockcroft-Gault
formula.
16 Glomerular filtration rate was estimated by
measuring 51Cr-EDTA clearance.
17 The diagnosis of SCD
was estimated by a pH 8.6 cellulose acetate electrophoresis,
a solubility test, and HbA2 and HbF quantification.
14 All
patients who are treated at the Hematology and
Hemotherapy Center routinely underwent the aforemen-
tioned exams, which facilitated this retrospective study.
BMD was measured at the femoral neck and lumbar spine
using a Lunar DPXH densitometer. We classified the
patients according to the World Health Organization
18
using the T-score, which represents the number of standard
deviations (SD) from the mean of normal subjects. Values
below -2.5 at one or both sites were defined as osteoporosis.
Values below -1 and above -2.5 were defined as osteopenia,
and values above -1 at both sites were considered normal.
18
The study cohort included 65 patients (40 females and 25
males) with a median age of 32.5 years (20-30 years old
(y.o.), n = 17; 31-40 y.o., n= 25; 41-50 y.o., n= 17; and 51-64
y.o., n= 6). Patients who were receiving hydroxyurea were
also included in the study. Patients with HbSC and HbSb
+
genotypes were excluded from the study. The National
Ethical Committee Board approved the study, and all
patients provided written informed consent.
Statistical analyses
Clinical characteristics were compared between patients
with normal BMD and those with low BMD (including both
osteopenia and osteoporosis), normal BMD and osteopenia
alone, normal BMD and osteoporosis alone and between
osteopenia and osteoporosis. Statistical analyses were
performed by comparing each independent variable
between two groups using the Mann–Whitney test for
numerical values and Fisher’s Exact Test for age. A p-value
of 0.05 or less was considered statistically significant.
RESULTS
Based on the BMD, patients were divided into three
groups, including those with normal BMD, those with
osteopenia, and those with osteoporosis. Osteopenia and
osteoporosis patients were classified as having reduced, or
low BMD. According to WHO criteria, 12 patients (18.5%;
4M/8F) had normal BMD, 37 patients (57%; 13M/24F) had
osteopenia, 16 patients (24.5%; 8M/8F) had osteoporosis,
and 53 patients had low BMD (81.5%, 21M/32F) at either
L1-L4 or the femoral neck site. Among the 60 HbSS patients,
10 (16.5%) had normal BMD, 34 (57%) had osteopenia and
16 (26.5%) had osteoporosis. Among the 5 HbSb
0 patients, 2
had normal BMD and 3 had osteopenia. The clinical
characteristics that were significantly associated with SCD
patients who had normal BMD, osteopenia and osteoporosis
are shown in Table 1.
A comparison of individuals with reduced BMD values
and those with normal BMD values revealed increased LDH
(median = 535 U/L vs. 883.5 U/L; p,0.0149) and an
elevated reticulocyte fraction (median = 8.6% vs. 11.75%;
p,0.0124) in the individuals with reduced BMD. LDH levels
were also significantly higher in individuals with osteope-
nia compared with those with normal BMD values. Patients
with osteoporosis presented with increased LDH and
reticulocyte counts and decreased Hb compared with
individuals with normal BMD values (p,0.05). Hemolysis
was statistically increased in patients with osteoporosis
compared with those with osteopenia, as indicated by the
Table 1 - Clinical characteristics of patients with SCD who have normal BMD, osteopenia or osteoporosis. Data are
presented as minimum-maximum (median). All p-values were obtained using the Mann Whitney test for numerical
values and Fisher’s Exact Test for age.
Normal n=12 (18.5%)
Osteopenia n=37
(57%) Osteoporosis n=16 (24.5%)
(p) NL vs.
Osteopenia
(p) NL vs.
Osteoporosis
(p) Osteopenia vs.
Osteoporosis
Male/Female 4/8 13/24 8/8 1.0 0.45 0.37
Age (years) 25-49 (32.5) 20-64 (35) 26-64 (41.5) 0.41 0.0165 0.0095
BMI (kg/m
2) 14.42-27.39 (18.45) 15.94-29.90 (20.65) 16.73-26.63 (19.36) 0.113 0.422 0.17
GFR (EDTA) (mL/min/
1.73m
2)
83.0-219.0 (115.5) 48.0-224.0 (125.05) 39.4-132.0 (102.0) 0.69 0.20 0.02
LDH (U/L) 384-1141 (535) 316-2040 (846) 506-2605 (1123.5) 0.0469 0.0005 0.0037
Hb (g/dL) 6.8-10.5 (8.55) 5.5-12.5 (8.5) 4.6-9.9 (7.8) 0.35 0.0113 0.042
Retc (%) 4.26-12.54 (8.6) 3.67-33.62 (10.62) 9.5-34.44 (15.55) 0.149 ,0.0001 0.0008
Retc (610
9/L) 142.5-394.1 (216.95) 112.0-759.5 (231.1) 219.8-617.5 (359.25) 0.58 0.0018 0.0055
Abbreviations: BMI: bone mass index; GFR: glomerular fibration rate; LDH: lactate dehydrogenase; Hb: hemoglobin; Retc: reticulocyte.
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802increased LDH and reticulocyte counts (both by absolute
values and percentage) and decreased Hb (Figure 1). The
osteoporosis patient group was older and had a lower GFR
than the osteopenia group. There was no significant
difference between the groups with regard to gender,
BMI, serum creatinine, estimated creatinine clearance, and
microalbuminuria.
DISCUSSION
Our study indicated a high prevalence (81.5%) of low
BMD in adults with HbSS or HbSb
0 and revealed an
association between low BMD and high LDH, high
reticulocyte counts, and low hemoglobin levels in this
population. The group of patients with osteoporosis also
displayed a higher age and a lower GFR than patients with
osteopenia. The life expectancy of SCD patients has
improved due to the implementation of comprehensive
sickle cell care. Concomitant with this increase in life
expectancy, there is a desire to emphasize long-term health
maintenance in these patients. Osteoporosis may be one of
the major public health problems in SCD patients, particu-
larly if the onset takes place at an early age.
Osteopenia and osteoporosis are well-known comp-
lications associated with SCD and thalassemia major;
however, the information in the literature regarding the
pathophysiology of bone diseases in adults with SCD is very
limited.
3,6,10 Bones may be affected by both hemolytic and
vaso-occlusive processes in SCD.
2 In our study, we found a
correlation between low BMD and increased erythropoietic
activity, which was assessed by the strong correlation
between LDH, reticulocytes and Hb levels.
Serum lactate dehydrogenase has long been considered a
useful clinical marker of intravascular hemolysis. Serum
levels of lactate dehydrogenase are mildly elevated in
illnesses involving extravascular hemolysis, such as immune
hemolytic anemia; however, lactate dehydrogenase levels are
substantially elevated in conditions associated with intravas-
cular hemolysis, such as thrombotic thrombocytopenic
purpura and paroxysmal nocturnal hemoglobinuria.
Figure 1 - (A) Lactate dehydrogenase levels (LDH); (B) Hemoglobin (Hb) values; (C) Percentage of reticulocytes and (D) Absolute
reticulocyte counts in patients with normal bone mass density (BMD), reduced BMD (both osteopenia and osteoporosis), osteopenia
alone and osteoporosis alone, as indicated in the figure. The horizontal bars indicate the median. The p-values are indicated in the
figure.
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803Although two thirds of all hemolysis occurs extravascularly
in SCD, the remaining one third of red cells undergoes
intravascular hemolysis.
19 Rapid scavenging of nitric oxide
(NO)
16 by cell-free hemoglobin and oxygen free radicals,
together with low concentrations of the substrate L-
arginine,
20,21 reduces NO bioavailability in SCD. NO plays
a role as a cytoprotective mediator, inhibiting the gene
transcription of pro-adhesive and pro-inflammatory mole-
cules, such as endothelial VCAM-1 and P-selectin.
22
Therefore, we speculated that reduced NO bioavailability
could be related to low BMD in SCD. Moreover, in our study,
older adults with SCD were found to have a higher
prevalence of low BMD, which could be related to the
chronic inflammatory state of SCD. The pathophysiology of
low BMD in patients with chronic inflammation has been
suggested to be related, in part, to increased bone resorption
that results from the action of inflammatory cytokines, such
as TNF-alpha and IL-6.
23 Inflammatory cytokines are
similarly elevated in patients with SCD
24,25 and may play a
role in the pathophysiology of low BMD.
Chronic and severe anemia places a burden on the bone
marrow, with increased erythropoiesis causing hyperplasia
of the bone marrow, a decrease in the trabecular network
and osteopenia
7 and subsequent bone destruction.
6 Some
studies, however, found no correlation between Hb levels
and BMD values.
7,10 Corroborating our findings, Sarrai et
al.
3 also described an association between abnormal BMD
and reduced Hb levels. These conflicting data could be a
result of subject selection. Both previous studies included
patients with SS, SC, Sb
+ and Sb
0 hemoglobinopathies. Our
study did not include SC and Sb
+ patients, who typically
present with high Hb levels, decreased hemolysis and
normal GFR values that might obscure the impact of
hemolysis and GFR on BMD.
Patients with osteoporosis also presented with mild renal
impairment when compared to those with osteopenia. Renal
impairment might be implicated in the pathogenesis of bone
loss in these patients because increased bone resorption and
osteoporosis are known to occur in patients with renal
dysfunction.
26 However, hyperparathyroidism was not
evaluated in these patients, and further studies would be
necessary to better elucidate the mechanism by which renal
impairment affects bone loss in SCD patients. Interestingly,
Miller et. al
10 found no correlation between parathyroid
hormone concentrations and osteoporosis in SCD patients.
Other clinical characteristics that are known to be risk
factors for osteoporosis, such as the age of menopause in
female patients, the amount of physical exercise, serum
calcium values, other nutritional facts, or family history,
were not evaluated in this study. Additional studies are
necessary to reveal the independent impact of each of these
characteristics on bone involvement.
CONCLUSION
A high prevalence of reduced BMD was found in
Brazilian patients with SCD, and this loss of BMD was
associated with hemolysis, as indicated by high LDH levels,
elevated reticulocyte counts and low Hb levels. Although
osteoporosis does not usually cause noticeable symptoms in
patients who are accustomed to living with pain, osteo-
porosis may nevertheless lead to severe complications.
There is no specific preventative therapy for this population,
and, as a result, SCD health care should focus on calcium
intake, vitamin D supplementation and reductions in
hemolysis. Future research should evaluate the ability of
hydroxyurea or pharmacological therapies to prevent bone
mass loss in patients with SCD and low BMD.
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